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Vα24-invariant natural killer T (NKT) cells have shown potent 
anti-tumor properties in murine tumor models and have 
been linked to favorable outcomes in patients with cancer. 
However, low numbers of these cells in humans have hindered 
their clinical applications. Here we report interim results 
from all three patients enrolled on dose level 1 in a phase 1 
dose-escalation trial of autologous NKT cells engineered to 
co-express a GD2-specific chimeric antigen receptor (CAR) 
with interleukin-15 in children with relapsed or resistant 
neuroblastoma (NCT03294954). Primary and secondary 
objectives were to assess safety and anti-tumor responses, 
respectively, with immune response evaluation as an addi-
tional objective. We ex vivo expanded highly pure NKT cells 
(mean ± s.d., 94.7 ± 3.8%) and treated patients with 3 × 106 
CAR-NKT cells per square meter of body surface area after 
lymphodepleting conditioning with cyclophosphamide/fluda-
rabine (Cy/Flu). Cy/Flu conditioning was the probable cause 
for grade 3–4 hematologic adverse events, as they occurred 
before CAR-NKT cell infusion, and no dose-limiting toxicities 
were observed. CAR-NKT cells expanded in vivo, localized to 
tumors and, in one patient, induced an objective response with 
regression of bone metastatic lesions. These initial results 
suggest that CAR-NKT cells can be expanded to clinical scale 
and safely applied to treat patients with cancer.
Vα24-invariant NKT cells are a sublineage of innate-like T cells 
that express the Vα24-Jα18 invariant T  cell receptor α-chain and 
react to glycolipids presented by CD1d1. In contrast to conven-
tional T cells that require priming to become functionally compe-
tent, NKT cells undergo a unique differentiation program in the 
thymus through which they acquire NK-like properties, including 
potent cytotoxicity, rapid cytokine secretion and effective traffick-
ing to tissues2. Unlike NK cells, however, NKT cell target recogni-
tion is CD1d restricted, analogous to HLA restriction in T  cells3. 
Although most tumors are CD1d negative and cannot be directly 
targeted by NKT cells3, NKT cells migrate to tumor sites in response 
to tumor-derived chemokines4,5, and their presence in primary 
tumors correlates with favorable outcomes in some cancer types4,6. 
Within tumors, NKT cells can kill tumor-associated macrophages5,7, 
which promote tumor growth and metastasis8. Moreover, NKT cell 
activation indirectly promotes NK- and T cell-mediated anti-tumor 
responses1. Indeed, transactivation of CD8 T and NK cells has been 
a consistent finding in clinical studies designed to activate endog-
enous NKT cells9 or adoptively transfer ex vivo-activated NKT cells 
into patients with cancer10,11. However, the earlier trials summarized 
in Motohashi et al.10 had low frequencies of NKT cells in the infu-
sion products, and the later trial11 did not examine NKT cell traf-
ficking to tumor sites.
The innate and adaptive immune-modulating properties of 
NKT cells are largely absent in the polyclonal T cell products cur-
rently used for cell therapy, and NKT cells might, therefore, be an 
alternative cellular platform for CAR-redirected immunother-
apy12,13. However, the low frequency of NKT cells in human periph-
eral blood mononuclear cells (PBMCs) (~0.1%) and even lower 
prevalence in patients with cancer14 have necessitated the develop-
ment of new methods distinct from those used for T or NK cells to 
accomplish clinical-scale NKT cell expansion15.
Neuroblastoma (NB) cells selectively express high levels of 
GD2-ganglioside16. In a recent clinical trial of T cells expressing a 
third-generation GD2-specific CAR, the therapy was well tolerated, 
but none of the 11 patients with NB achieved an objective response17. 
To develop GD2-CAR-NKT cell therapy, we evaluated a series of 
constructs encoding a GD2-CAR with or without interleukin (IL)-
15, a cytokine that supports NKT cell survival12,18. Compared to 
GD2-CAR-NKT cells, NKT cells expressing a GD2-CAR-IL-15 con-
struct demonstrated superior in vivo persistence, tumor infiltration 
and anti-tumor activity in metastatic NB mouse models without 
causing evident toxicity19. We, therefore, initiated a first-in-human 
phase 1 clinical trial evaluating autologous CAR-NKT cells in eli-
gible children with relapsed or refractory NB (eligibility criteria 
presented in Supplementary Table 1). Primary and secondary objec-
tives were to assess safety and anti-tumor responses, respectively, 
with immune correlative studies as an additional objective. Here we 
present an interim analysis of results obtained from the first three 
patients on this study.
The treatment protocol included lymphodepleting conditioning 
on days −4, −3 and −2 (cyclophosphamide, 500 mg per m2 per dose; 
fludarabine, 30 mg per m2 per dose) followed by CAR-NKT cell 
infusion on day 0 (Extended Data Fig. 1). Patients were evaluated 
at weekly clinic visits. Adverse events (AEs) were collected from 
the start of lymphodepletion until 28 d after infusion and described 
according to the Common Terminology Criteria for Adverse 
Events, version 4. Patients underwent core biopsies of one involved 
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site at 2 weeks after infusion. Response to therapy was assessed at 
4 weeks after infusion by standard imaging techniques, including 
metaiodobenzylguanidine (MIBG), single-photon emission com-
puted tomography (SPECT) and bone marrow aspirates/biopsy 
(bone marrow-positive patients at time of enrollment).
The first three patients were male, ages 12, 12 and 6 years, with 
stage M disease according to the International Neuroblastoma Risk 
Group, owing to multifocal metastases (Extended Data Fig. 2)20. 
These patients had relapsed or refractory disease despite standard 
upfront and additional salvage therapies. The patients first under-
went apheresis, which yielded 9.11–20.54 × 109 PBMCs, and, after 
positive selection, 0.4–1.79 × 106 NKT cells were collected (Extended 
Data Fig. 3a and Supplementary Table 2). After stimulation with 
alpha-galactosylceramide-pulsed irradiated PBMCs and expansion, 
the final products reached 96.5%, 97.17% and 90.36% (mean, 94.7%) 
NKT cell purity for the three patients, respectively (Extended Data 
Fig. 3b and Supplementary Table 2). In contrast, in the most suc-
cessful clinical-scale NKT cell expansion to date in which isolated 
NKT cells were, instead, stimulated with CD3/CD28 agonistic anti-
bodies, the mean NKT purity was 54.4% across nine patients (range, 
13–87%)11. CAR-positive cells accounted for 34.71%, 20.18% and 
70.4% of the NKT cell population for the three patients, respectively 
(Extended Data Fig. 3b and Supplementary Table 2). The infused 
products in all patients were predominantly CD4 positive and con-
tained large fractions of cells positive for CD62L (40.0–78.5%), a 
marker linked to in vivo persistence of CAR-NKT cells in preclini-
cal models15 (Supplementary Fig. 1).
The first three patients represent all patients on dose level 1: 
3 × 106 GD2-CAR-IL-15 NKT cells per m2. The CAR-NKT cells were 
well tolerated, and no dose-limiting toxicities (DLTs), including 
cytokine release syndrome (CRS) or neurotoxicities, were observed. 
Cy/Flu was the probable cause of grade 3–4 AEs, including reduc-
tions in total white blood cells and red blood cells, as well as abso-
lute lymphocyte, monocyte and platelet counts, as they were present 
by day 0 before CAR-NKT cell infusion (Extended Data Figs. 4 
and 5a). This is consistent with AEs observed in patients with NB 
after lymphodepletion who were treated with GD2-CAR T cells17. 
Analysis of major lymphoid and myeloid subsets (additional objec-
tives) revealed several notable differences between patients. Patient 
1 showed limited recovery of any subsets except NK cells; patient 2 
showed expansion of NK cells, Tregs and monocytes after week 2; 
and patient 3 retained residual CD8 T cells after lymphodepletion 
that increased by week 4 (Extended Data Fig. 5b).
In all patients, we detected an increase above baseline in periph-
eral NKT cell frequency (Fig. 1a and Extended Data Fig. 6) and 
absolute number (Fig. 1b), both of which were sustained until the 
end of the 4-week evaluation period. CAR-NKT cells were also 
detected in all patients, and similar kinetics were found by flow 
cytometry and quantitative polymerase chain reaction (qPCR) 
(Fig. 1c,d). Absolute CAR-NKT cell numbers were lowest in patient 
1 and highest in patient 3, in whom CAR-NKT cells expanded 
throughout the 4-week evaluation. Products for patients 1, 2 and 3 
underwent 15, 14 and 9 days ex vivo culturing, respectively, which 
might have influenced the in vivo expansion of the infused cells21. 
Single-cell RNA sequencing (scRNA-seq) analysis of the infused 
CAR-NKT cell products revealed the presence of nine distinct 
gene expression clusters that were present in all three patients, 
albeit at different frequencies (Fig. 1e, Supplementary Fig. 2 and 
Supplementary Table 3). CAR transgene expression was concen-
trated in cluster 3, which was also enriched in gene sets associated 
with central memory versus effector memory and activation versus 
exhaustion (Fig. 1f–h). We observed that the frequency of cluster 3 
(CAR-positive and CAR-negative cells) was highest in the product 
of patient 3 (Supplementary Fig. 3). Cluster 3 was further charac-
terized by co-expression of genes associated with co-stimulation 
(TNFRSF4, encoding OX40), central memory (SELL, encoding 
CD62L) and the Wnt pathway (Extended Data Fig. 7a). Flow cytom-
etry confirmed the existence of CD62L+OX40+ and CD62L+LEF1+ 
(a Wnt pathway transcription factor) NKT cell subsets in all prod-
ucts (Extended Data Fig. 7b,c). We also observed high expression 
levels of metabolic genes in cluster 3 (Extended Data Fig. 8a). A 
bioenergetics analysis demonstrated that cells from patients 2 and 3 
had a significantly higher rate of glycolysis (P < 0.01) and glycolytic 
capacity (P < 0.001) than cells from patient 1, and that cells from 
patient 2 had a higher spare respiratory capacity than cells from 
patient 3 (P < 0.01) (Extended Data Fig. 8b–e).
Next, we performed a serial tumor challenge assay in which 
NB cells were replenished every 5 d for five rounds, as previ-
ously described19 (Extended Data Fig. 9a). After the third round, 
CAR-NKT cells from patient 1 progressively lost cytotoxic activity, 
whereas those from patients 2 and 3 retained the ability to kill NB 
cells through the fifth round (P < 0.01; Extended Data Fig. 9b,c). 
CAR-NKT cells from patients 2 and 3 also showed enhanced pro-
liferative response compared to cells from patient 1 throughout the 
first four rounds of co-culture (P < 0.05; Extended Data Fig. 9d).
Homeostatic cytokines, including IL-7 and IL-15, promote the 
expansion of adoptively transferred lymphocytes after lymphode-
pletion17,22. In these patients, peripheral blood IL-15 levels increased 
around the time of CAR-NKT cell infusion and returned to approxi-
mately baseline by week 4, whereas IL-7 remained close to base-
line throughout (Extended Data Fig. 10). The observed pattern of 
serum IL-15 changes is consistent with the expected effect of the 
lymphodepleting conditioning and is unlikely to be related to the 
infused GD2-CAR-IL-15 NKT cells. This is also consistent with pre-
clinical data in which serum IL-15 remained undetectable in NSG 
mice treated with a dose of GD2-CAR-IL-15 NKT cells 1,000-fold 
higher than that received by patients on this study19.
To evaluate CAR-NKT cell tumor localization, we performed 
flow cytometry analyses on a post-infusion biopsy specimen 
from patient 1. Within the small population of tumor-infiltrating 
lymphocytes, NKT cells were present at a higher frequency than 
detected in peripheral blood lymphocytes; notably, 85.7% of 
tumor-infiltrating NKT cells expressed the GD2-CAR (Fig. 2a). 
The CAR transgene was undetectable by qPCR in a small quantity 
of DNA isolated from this sample. Although not measurable by 
flow cytometry, qPCR for the CAR transgene detected 60.4 and 
23.7 copies per microgram of DNA in patients 2 and 3, respec-
tively (Supplementary Table 4). We also examined the ability of 
CAR-NKT cells to penetrate the bone marrow in patient 1, the 
only patient with bone marrow metastases. As with the solid tumor 
Fig. 1 | CAR-NKT cells expand and persist in patients with relapsed or refractory NB. a, Flow cytometry plots showing pre- and post-infusion NKT cell 
frequency and GD2-CAr expression in peripheral blood samples from patient 3. Histogram shows CAr expression in week 3 after infusion of NKT cells 
(red) compared to T cells (gray) as a negative control. SSC, side scatter. b, Absolute NKT cell numbers in peripheral blood as determined by flow 
cytometry and absolute lymphocyte counts for the three patients. c, Absolute number of circulating CAr-NKT cells as determined by flow cytometry.  
d, Fold change in GD2-CAr transgene DNA copy number per milliliter of peripheral blood compared to 3-hour post-infusion baseline as determined by 
qPCr. e, Unsupervised clustering of single-cell gene expression visualized using the UMAP algorithm in pre-infusion products. each point represents  
a single cell (9,323 cells total); cells are colored by cluster. f, expression of GD2-CAr transgene after secondary analysis (using primers specific to  
the GD2-CAr) overlaid on the UMAP two-dimensional projection. g, Comparative gene expression of central memory versus effector memory and  
(h) activation versus exhaustion markers from reference gene signatures (Methods) overlaid on the UMAP two-dimensional projection.
biopsy, we found a higher percentage of NKT cells in the bone mar-
row metastases than in the peripheral blood, but, in contrast, only 
a small fraction of these cells expressed the GD2-CAR (33.4 cop-
ies per microgram of DNA by qPCR) (Fig. 2b and Supplementary 
Table 4). We observed higher levels of GD2 expression in NB cells 
in the tumor biopsy of patient 3 and in the bone marrow of patient 
1 than in the tumor biopsy of patient 1, suggesting the possibility 
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Therapeutic responses, the secondary objective of this study, 
were examined using the International Neuroblastoma Response 
Criteria (INRC)23 and by comparing pre- and post-infusion NB 
burden using Curie scoring, which has prognostic value24. Patient 1 
had stable disease as determined by the INRC, and his Curie score 
did not change after CAR-NKT cell treatment (Fig. 2c). Patient 3 
had stable disease, and his Curie score decreased from 7 to 5. Patient 
2 had a partial response and a change in Curie score from 2 to 1; 
SPECT- and MIBG-merged scan images revealed a dramatic reduc-
tion in the size and MIBG uptake of a bone metastasis in that patient 
(Fig. 2d). The patient consequently received salvage therapy and 
achieved a complete response that lasted approximately 6 months 
(Extended Data Fig. 2).
In conclusion, our initial results demonstrate that NKT cells 
can be expanded to clinical scale with high purity, genetically engi-
neered to express a CAR and used to safely treat patients with NB. 
In addition, we found that CAR-NKT cells can be detected in the 
peripheral blood where they expand after infusion, traffic to bone 
metastases and the bone marrow and induce tumor regression in 
heavily pretreated patients with relapsed or refractory disease. This 
interim analysis suggests that the in vivo persistence and anti-tumor 
potential of CAR-NKT cells could be influenced by cell characteris-
tics, including retention of the central memory program, metabolic 
fitness and resistance to exhaustion, as well as other factors, includ-
ing the duration of product manufacturing and retention of target 
antigen on the tumor cells. These hypotheses are being tested while 
the study continues to enroll patients.
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Fig. 2 | CAR-NKT cells infiltrate tumor sites and mediate tumor regression. a, Flow cytometry plots showing NKT cells as a percentage of total 
tumor-infiltrating lymphocytes 2 weeks after infusion in a biopsy from patient 1. Histogram shows CAr expression in these NKT cells (red) compared to 
T cells (gray) as a negative control. b, Flow cytometry plots showing NKT cells in bone marrow aspirate from patient 1 4 weeks after infusion. Histogram 
shows CAr expression in these NKT cells (red) compared to T cells (gray) as a negative control. c, Change in Curie score at 4 weeks after infusion versus 
before infusion for the three patients. d, Merged SPeCT and MIBG uptake scans showing a metastatic sternum lesion from patient 2 at indicated time points.
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Biosystems). Copy number was normalized to 1 μg of DNA isolated from PBMCs. 
Lymphodepleting chemotherapy with Cy/Flu decreases total white blood cell 
numbers, resulting in an artificial increase in transgene copy number as measured 
by PCR when normalized to DNA only; therefore, transgene copy number was 
calculated per milliliter of peripheral blood.
Multiplex cytokine assay. Serum cytokine levels were measured using the 
Milliplex MAP magnetic bead-based human cytokine pre-mixed 38-plex kit 
(EMD Millipore) on the Luminex 200 system with xPONENT software (Luminex) 
according to the manufacturer’s instructions.
Flow cytometry analyses. GD2-CAR NKT cells were detected in peripheral blood 
and patient biopsy samples using the following antibodies: FITC-conjugated 
anti-TCR Vβ11 (clone C21, Beckman Coulter), PE-conjugated anti-iNKT 
(6B11, BD Biosciences), BV421-conjugated anti-CD3 (SK7, BD Biosciences) 
and an anti-idiotype GD2-CAR antibody (1A7), produced in-house using 
murine hybridoma HB-11786 (ATCC) and custom conjugated with APC 
(BioLegend). Evaluation of patient products also included PE-Cy7-conjugated 
anti-CD62L (DREG56) and APC-H7-conjugated anti-CD4 (SK3), both from 
BD Biosciences. To evaluate lymphoid subsets, the following antibodies were 
used: FITC-conjugated anti-CD3 (SK7), APC-H7- or APC-conjugated anti-CD8 
(SK1), BV510- or PE-conjugated anti-CD4 (SK3), PE-Cy7-conjugated anti-CD25 
(2A3), BV421-conjugated anti-CD127 (HIL-7R-M21), PE-Cy7-conjugated 
anti-CD56 (NCAM16.2) and BV421-conjugated anti-CD19 (SJ25C1), all from 
BD Biosciences. To evaluate myeloid subsets, the following antibodies were used: 
PE-Cy7-conjugated anti-CD11b (ICRF44), BV510-conjugated anti-HLA-DR 
(G46-6), APC-H7-conjugated anti-CD14 (MΦP9), PE-conjugated anti-CD16 
(B73.1) and FITC-conjugated anti-CD15 (MMA), all from BD Biosciences. 
Intracellular staining was performed using the Foxp3/transcription factor staining 
buffer set (eBioscience). Dead cells were excluded using fixable viability dye 
eFluor 780 (eBioscience), and the following monoclonal antibodies were used: 
FITC-conjugated anti-CD3 (UCHT1), BV605-conjugated anti-CD4 (RPA-T4), 
PE-Cy7-conjugated anti-CD62L (DREG-56) and BV421-conjugated anti-CD134 
(ACT35), all from BD Biosciences, as well as AF647-conjugated anti-GD2 
CAR 1A7 and PE-conjugated anti-LEF1 C12A5 (Cell Signaling Technology). 
To evaluate NB cells, the following antibodies were used: PE-Cy7-conjugated 
anti-CD56 (NCAM16.2), FITC-conjugated GD2 (14.G2A) and PerCP-conjugated 
CD45 (2D1), all from BD Biosciences. Sequential flow cytometry gating strategies 
can be found in Supplementary Fig. 5. Samples were analyzed on an LSR-II 
five-laser flow cytometer using BD FACSDiva software, version 6.0, and FlowJo 
10.6.1 (BD Biosciences).
Metabolic analyses. Oxygen consumption rates and extracellular acidification rates 
were measured in pre-adjusted pH 7.4 Seahorse XF RPMI medium, supplemented 
with 2 mM L-glutamine alone (glycolysis stress test) or associated with 10 mM 
glucose and 1 mM pyruvate (mito stress test), using a 96-well XFe Extracellular 
Flux Analyzer (all from Agilent Technologies). Measurements were performed 
with 200,000 cells per well under basal conditions and in response to 1.5 μM 
oligomycin, 2 μM fluoro-carbonyl cyanide phenylhydrazone, 0.5 μM rotenone, 
0.5 μM antimycin A or 50 mM 2-deoxy-D-glucose (all from Sigma-Aldrich).
Serial tumor challenge assay. Patient CAR-NKT cells and CHLA-255 NB cells 
transduced with green fluorescent protein were co-cultured in a 24-well plate 
using fresh culture medium at a 1:1 effector-to-target (E:T) ratio, respectively. 
Every other day, 50 U ml−1 of IL-2 was added. Five days later, cells were harvested, 
quantified by trypan blue exclusion and analyzed for NKT and NB cell markers by 
flow cytometry. CAR-NKT cells were then replated at a 1:1 E:T ratio with fresh NB 
cells in fresh cell culture medium to start the next round of tumor co-culture. The 
process was repeated for five rounds.
Statistics for in vitro functional experiments. Two-way analysis of variance with 
Tukey’s correction for multiple comparisons was used to determine the effect 
of two independent variables on a continuous dependent variable (Extended 
Data Figs. 8 and 9). An unpaired t-test was used to compare the averages of two 
independent groups (Extended Data Fig. 10e; patient 2 versus patient 3 with three 
technical replicates each). Statistics were computed using GraphPad Prism 7.0 
(GraphPad Software). Differences were considered significant when the P value 
was less than 0.05.
Cell hashing and scRNA-seq library construction. Pre-infusion products from 
patients 1–3 were labeled with different barcoded TotalSeq-C Hashtag antibodies 
(anti-β2 M (clone 2M2) and CD298 (clone LNH-94), BioLegend) for 30 min at 
room temperature in RPMI (Life Technologies) + 2% FBS (Life Technologies). 
Cells were then washed three times in PBS (Life Technologies) + BSA 0.04% 
(VWR). Finally, cells were pooled and loaded into the Chromium Next GEM 
Single Cell 5′ Library and Gel Bead Kit version 1.1 workflow (10× Genomics). 
Single-cell RNA and cell hashing26 library preparation was performed according 
to the manufacturer’s instructions. Libraries were sequenced by GENEWIZ on the 
NovaSeq 6000 System using the S4 2 ×150 kit (Illumina).
Methods
Detailed information on experimental design and reagents can be found in the Life 
Sciences Reporting Summary.
Study development and design. The ‘GD2 Specific CAR and Interleukin-15 
Expressing Autologous NKT Cells to Treat Children With Neuroblastoma’ 
(GINAKIT2) phase 1 clinical trial was reviewed and approved by the Protocol 
Review Committee, the Institutional Biosafety Committee and the Institutional 
Review Board at Baylor College of Medicine, as well as the Recombinant DNA 
Advisory Board of the National Institutes of Health and the US Food and Drug 
Administration (FDA). The study was conducted at Texas Children’s Hospital, 
Baylor College of Medicine, in Houston, Texas, in accordance with Declaration of 
Helsinki principles. All participants and/or their legal guardians provided written 
informed consent/assent upon enrollment and before administration of the cells. 
The GINAKIT2 study is a phase 1 clinical trial using standard 3 + 3 dose escalation, 
as described in the clinical trial protocol (Supplementary Information). Patients 
were enrolled between August 20, 2018, and July 29, 2019. Eligibility inclusion 
criteria for treatment included relapsed or refractory high-risk NB, age older than 
1 year and less than 21 years, appropriate bone marrow, liver, renal, cardiac and 
respiratory function and absence of human anti-mouse antibodies (in patients 
with previous exposure to murine antibodies). Exclusion criteria included rapidly 
progressing disease, receiving other investigational drugs, immunosuppressive 
therapy or history of severe previous toxicity to cyclophosphamide or fludarabine. 
Full eligibility criteria are listed in Supplementary Table 1.
Clinical safety and outcome assessment. AEs were collected from the start of 
lymphodepletion until 28 d after infusion and described according to the Common 
Terminology Criteria for Adverse Events, version 4. A DLT was defined as: 1) any 
hematological or non-hematological grade 3–5 toxicity that is considered to be 
primarily related to the CAR-NKT cells; 2) CRS and neurological toxicities grade 
3 and 4; expected reactions seen with the use of CAR-based immunotherapy, 
such as fever or hypotension lasting less than 72 h, will not be considered 
DLTs; symptoms lasting more than 72 h will be considered DLTs; 3) any other 
unexpected grade 3 or higher toxicity thought to be related to, or resulting from, 
CRS or due to neurological toxicity is included in the definition of DLT; and 4) 
grade 3 and 4 CRS or neurological toxicities that are persistent beyond 72 h will 
be reported to the FDA in an expedited fashion and will be considered DLTs. 
Anti-tumor responses were defined by comparing standard three-dimensional 
imaging (computed tomography and magnetic resonance imaging), MIBG scan 
and bone marrow aspirates/biopsies from pre- and post-CAR-NKT cell infusion. 
Anti-tumor responses were examined using the International Neuroblastoma 
Response Criteria22 and by measuring the difference in pre- and post-infusion 
Curie scoring23.
Clinical-grade vector production. The clinical-grade vector encoding the 
GD2-CAR-IL-15 construct was produced at the current good manufacturing 
practices (cGMP) facility of the Center for Cell and Gene Therapy at Baylor 
College of Medicine. Briefly, the SFG plasmid encoding the GD2-CAR-IL-15 
construct was transfected into HEK-293T cells, which produce Gibbon ape 
leukemia virus pseudotype and Moloney murine leukemia virus-derived 
gamma-retroviral particles. The clinical vector was validated, tested according to 
cGMP guidance, cryopreserved and stored at −80 °C until use.
CAR-NKT cell manufacturing. PBMCs were isolated from peripheral blood 
leukapheresis products using Ficoll gradient purification, and NKTs were 
isolated using a special lot of anti-iNKT microbeads (Miltenyi Biotec) (tested 
according to FDA guidelines by BioReliance) and the CliniMACS instrument 
(Miltenyi Biotec). Enriched NKT cells were then stimulated with cGMP-grade 
alpha-galactocylceramide and (GlycoSyn)-pulsed PBMCs and cultured with IL-2 
and IL-21 (NCI, 200 U ml−1 and CellGenix, 10 ng ml−1, respectively). Culture 
supplementation with IL-21 is used to increase the frequency and functionality of 
CD62L+ NKT cells25. Cells were transduced with retroviral particles encoding the 
GD2-CAR-IL-15 construct in RetroNectin-coated plates (Takara Bio) for 72 h and 
then washed, replated and cultured at 38 °C for 9–15 d. CAR-NKT cell products 
(patients 1 and 2) that did not have sufficient numbers on day 10 were restimulated 
with alpha-galactocylceramide-pulsed PBMCs and expanded until sufficient 
numbers were met. At the end of manufacture, the product was evaluated using 
trypan blue staining and flow cytometry. Additionally, GD2-CAR transgene copy 
number was determined by qPCR.
Transgene copy number assessment. GD2-CAR transgene copy number was 
evaluated in peripheral blood and tumor biopsy samples. Genomic DNA was 
extracted using the QIAamp DNA Blood Minikit (Qiagen) according to the 
manufacturer’s instructions, and transgene copy number was measured by 
TaqMan qPCR gene expression assay using primers (forward: 5′-GCTGCACCA 
ACTGTATCCATCTT-3′; reverse: 5′-GGTCCAGACTGCTGAAGCT-3′) and 
probe (5′-CACCCGACCCACCACC-3′) sequences complementary to the 
GD2-CAR sequence (Applied Biosystems). qPCR was performed in 25-μl 
reaction volumes using the ABI 7900HT Sequence Detection System (Applied 
scRNA-seq data processing. Two separate experiments were performed. The 
samples were processed similarly, and data were integrated as follows. Briefly, 
matrices were produced using the Cell Ranger Single-Cell Software Suite 
(v3.1.0) with a human transcriptome reference (GRCh38) with the following 
modifications: 1) the GD2-CAR construct sequence was added; 2) to avoid an 
erroneous cross-mapping of GD2-CAR scFv transcripts to immunoglubulin 
genes, the immunoglubulin sequences were removed from the reference. Data 
analysis was performed using Seurat (v3.1.1), which is publicly available. Product 
samples were de-hashed, and singlets were extracted by applying HTODemux27 on 
CLR-normalized data with 0.95 as the positive quantile. RNA data were normalized 
using SCTransform28 regressed on percent of mitochondrial genes and integrated 
using the FindIntegrationAnchors function and the CCA method29. Dimensionality 
was reduced using the Uniform Manifold Approximation and Projection (UMAP) 
algorithm. Differential gene expression was performed using the Seurat function 
FindAllMarkers default settings; a minimum fraction of cells expressed a gene of 25% 
(mn.pct = 0.25) and a log2 fold change of 0.2 (logfc.threshold = 0.2). Comparative 
gene expression of central memory versus effector memory and activation versus 
exhaustion markers was performed using published reference gene signatures30–33.
GD2-CAR capture from scRNA-seq complementary DNA library. To increase 
capture rates of the GD2-CAR construct in the single-cell RNA sequencing 
experiment, we designed a hemi-nested PCR approach that enables the  
capture of the 10× cell barcode and the GD2-CAR. Briefly, after complementary 
DNA PCR amplification, 2 μl were used for a first PCR amplification  
using the primers ( fo rw ard: 5 ′- AA TG AT AC GG CG AC CA CC GA GA 
 TC TA CA CT CT TT CCCTACACGACGCTC-3′ (10× Genomics) and reverse: 
5′-CTGGCTTCTGCAGGTACCAATG-3′) using Kapa HiFi Polymerase  
(Kapa Biosystems) and purified using 0.8× reaction volume SPRI beads  
(Beckman Coulter). The product of the first PCR was further amplified by a second 
PCR using the primers (forward: 5′-AATGATACGGCGACCACCGAGATCT-3′ 
(10× Genomics) and reverse: 5 ′- CT CG TG GG CT CG GA GA TG TG TA TA AG AG 
AC AG GG GT CA GC AA AATATCTCTAGAGCACTGG-3′) using  
Kapa HiFi Polymerase and purified using 0.8× reaction volume  
SPRI beads. Finally, the GD2-CAR library was indexed using  
the primers (forward: 5′-AATGATACGGCGACCACCGAGATC 
TACACTCTTTCCCTACACGACGCTC-3′ (10× Genomics) and reverse: 
5′-CAAGCAGAAGACGGCATACGAGATTGTGTATAGTCTCGTGGGCTCGG
-3′) using Kapa HiFi Polymerase and purified using 0.7× reaction volume SPRI 
beads. Libraries were sequenced by GENEWIZ on a NovaSeq 6000 System using 
the S4 2 × 150 kit (Illumina). Sequencing data were aligned to the GD2-CAR 
construct using Bowtie2 (ref. 33). Reads that were successfully aligned were then 
assigned to cells by matching their barcode against the CellRanger’s barcode 
whitelist, without allowing for any base mismatch. All reads belonging to one cell 
were treated as vertices in a graph and were connected by an edge if the hamming 
distance between their unique molecular identifier was 0 or 1. All reads belonging 
to a connected component of this graph were treated as PCR duplicates and 
counted as a single GD2-CAR RNA molecule.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All requests for raw and analyzed data and materials will be promptly reviewed by 
the Baylor College of Medicine Licensing Group to verify whether the request is 
subject to any intellectual property or confidentiality obligations. Patient-related 
data not included in the paper were generated as part of the clinical trial and might 
be subject to patient confidentiality restrictions. Any data and materials that can be 
shared will be released via a material transfer agreement. All raw data for single-cell 
sequencing have been deposited in the Gene Expression Omnibus with the 
accession code GSE154037. Source data are provided with this paper.
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Extended Data Fig. 1 | Clinical trial design and enrollment. a, Trial design: Cyclophosphamide/fludarabine (Cy/Flu) chemotherapy is given on days -4, -3, 
and -2 (purple arrows). CAr-NKTs are infused on day 0 (green arrow). Tumor biopsy is performed at week 2 (blue arrow) and response evaluation with 
imaging at week 4 (range 4-6; orange arrow). Black arrows indicate clinic visits and peripheral blood analysis. b, enrollment CONSOrT flow diagram.
Extended Data Fig. 2 | Patient characteristics. Indicated variables shown for the three patients enrolled on dose level 1. INSS: International Neuroblastoma 
Staging System; **Cy: cyclophosphamide, Flu: fludarabine. $: Dose: CAr-NKT cells / m2. response criteria determined by revised International Neuroblastoma 
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Extended Data Fig. 3 | Characteristics of GD2-CAR-NKT cell products. Patient cells were manufactured in the cGMP facility of the Center for Cell and 
Gene Therapy at Texas Children’s Hospital and evaluated using multi-color flow cytometry. a, NKT frequency (CD3+iNKT+) in initial apheresis product 
for the three patients. b, NKT purity and CAr expression at the end of manufacturing prior to cryopreservation. Shown are results from one of two 
independent experiments that produced similar results.
tnevEmetsyS ydoB
Grade
Patient 1 Patient 2 Patient 3
Blood and lymphatic system 
disorders Anemia 3 2 1
Lymphocyte count decreased 4 4 3
Neutrophil count decreased 4 4 4
Platelet count decreased 4 1 1
White blood cell decreased 4 3 2





AST increased 1 1 1
Musculoskeletal and connective 
tissue disorders Back pain 1
Respiratory, thoracic and 
mediastinal disorders Epistaxis 1
Extended Data Fig. 4 | Adverse events. Patients were monitored for adverse events from the beginning of lymphodepletion (day -4) until day 28 (four weeks 
post-infusion). Adverse events were described using Common Terminology Criteria for Adverse events version 4.
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Extended Data Fig. 5 | Peripheral blood analysis pre- and post-infusion. Peripheral blood samples were collected at indicated timepoints and a) the 
frequency of total white blood cells (WBCs), absolute lymphocyte counts (ALC), and absolute monocyte counts (AMC) were quantified in a standard 
clinical laboratory at the Texas Children’s Cancer Center. b, Frequency of myeloid and lymphoid cell subsets were quantified by flow cytometry staining. 
Absolute numbers of these subsets in peripheral blood were determined using flow cytometry data and AMC or ALC, respectively. Live PBMCs were 



















































Patient 1 Patient 2
Extended Data Fig. 6 | Detection of CAR-NKT cells in treated patients pre- and post-infusion. Flow cytometry staining showing iNKT+Vβ11+ cells after 
gating on CD3+ cells and corresponding GD2-CAr expression in patients at indicated timepoints. T-cells served as a negative control for CAr staining. 
N.D.: not defined; indicates that assay was not performed at given timepoint.
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Extended Data Fig. 7 | Expression of central memory and WNT pathway genes in pre-infusion patient products. a, Gene expression in pre-infusion 
products from patients 1-3 for TNFRSF4 (encodes OX40), SELL (encodes CD62L), and genes related to Wnt-mediated signal transduction (https://
www.gsea-msigdb.org/gsea/msigdb/cards/WNT_SIGNALING.html) overlaid on the UMAP 2D projection. b, Cryopreserved patient products were 
thawed and rested overnight prior to evaluating surface expression of OX40 (CD134) and CD62L (bottom) by flow cytometry using the corresponding 
fluorochrome-conjugated isotype controls (top). c, LeF1 expression in relation to CD62L was analyzed using intracellular flow cytometry (bottom) with the 



































































































































Extended Data Fig. 8 | Expression of metabolic genes and bioenergetic analysis of pre-infusion patient products. a, Gene expression in pre-infusion 
products from patients 1-3 related to glycolysis (https://www.gsea-msigdb.org/gsea/msigdb/cards/KeGG_GLYCOLYSIS_GLUCONeOGeNeSIS) and 
oxidative phosphorylation (https://www.gsea-msigdb.org/gsea/msigdb/cards/KeGG_OXIDATIVe_PHOSPHOrYLATION) overlaid on the UMAP 2D 
projection. b, extracellular acidification rates (eCAr) and c) oxygen consumption rates (OCr) measured at baseline and in response to glucose (Glc), 
oligomycin (Oligo), 2-deoxy-D-glucose (2-DG), FCCP, or rotenone/antimycin A (r/A); data shown as mean ± SeM. d, Glycolytic and e) mitochondrial 
parameters derived from assay in b) and c) respectively; data shown as mean ± SD; P values by two-way ANOVA with Tukey’s correction for multiple 
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Extended Data Fig. 9 | Serial tumor challenge assay. a, Patient GD2-CAr NKTs and NB cell line CHLA-255 were co-cultured in a 24-well plate. Five days 
later, cells were harvested for quantification by trypan-blue exclusion and FACS analysis. NKT cells were then re-plated at a 1:1 effector-to-target ratio 
with fresh tumor cells in fresh cell culture medium to start the next round with five rounds total. b, representative flow cytometry analysis after round 4. 
Summary of c) tumor cell cytotoxicity and d) GD2-CAr NKT proliferation at the end of each five-day cycle. Data shown as mean ± SD from three technical 









































































Extended Data Fig. 10 | Peripheral blood cytokine levels. Peripheral blood was collected at indicated timepoints from the three patients and cytokine 
levels were quantified in triplicate by Luminex® assay. a, Cytokine expression is shown as log10 of pg/mL. b, IL7 and c) IL15 levels for the three 
patients at indicated timepoints. d, Peak IL15 concentration. Data shown as mean ± SD from three technical replicates (b-d); P values by unpaired 
two-tailed t-test (d).
